Anti-drug antibodies in Colombian patients with rheumatoid arthritis treated with Enbrel vs Etanar – Preliminary report

References

• Aarden L, Ruuls S, Wolbink G. 2008. Immunogenicity of anti-tumor necrosis factor antibodies: Toward improved methods of anti-antibody measurement. Curr Opin Immunol. 20:431–435.
   PubMed Web of Science ®Google Scholar
• Anderson P. 2005. Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles. Sem Arthritis Rheum. 34:19–22.
   PubMed Web of Science ®Google Scholar
• Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, Healey L, Kaplan S, Liang M, Luthra H, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumat. 31:315–324.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Talotta R, Salaffi F, Cassinotti A, Varisco V, Battellino M, Ardizzone S, Pace F, Sarzi-Puttini P. 2013. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 12:703–708.
   PubMed Web of Science ®Google Scholar
• Bathon J, Martin R, Fleischmann R, Tesser J, Schiff M, Keystone E, Genovese M, Wasko M, Moreland L, Weaver A, et al. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 343:1586–1593.
   PubMed Web of Science ®Google Scholar
• Descotes J. 2009. Immunotoxicity of monoclonal antibodies. MAbs. 1:104–111.
   PubMed Web of Science ®Google Scholar
• Dore R, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P. 2007. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 25:40–46.
   PubMed Web of Science ®Google Scholar
• Emi Aikawa N, de Carvalho J, Artur Almeida Silva C, Bonfá E. 2010. Immunogenicity of anti-TNF-α agents in autoimmune diseases. Clin Rev Allergy Immunol. 38:82–89.
   PubMed Web of Science ®Google Scholar
• Garces S, Demengeot J, Benito-Garcia E. 2013. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis. Ann Rheum Dis. 72:1947–1955.
   PubMed Web of Science ®Google Scholar
• Geiler J, Buch M, McDermott M. 2011. Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des. 17:3141–3154.
   PubMed Web of Science ®Google Scholar
• Hoshino M, Yoshio T, Onishi S, Minota S. 2012. Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Modern Rheumatol. 22:532–540.
   PubMed Web of Science ®Google Scholar
• Jamnitski A, Krieckaert C, Nurmohamed M, Hart M, Dijkmans B, Aarden L, Voskuyl A, Wolbink G. 2012. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis. 71:88–91.
   PubMed Web of Science ®Google Scholar
• Kelley B. 2009. Industrialization of mAb production technology: The bioprocessing industry at a crossroads. MAbs. 1:443–452.
   PubMed Web of Science ®Google Scholar
• Keystone E, Schiff M, Kremer J, Kafka S, Lovy M, DeVries T, Burge D. 2004. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multi-center, randomized, double-blind, placebo-controlled trial. Arthritis Rheumat. 50:353–363.
   PubMed Web of Science ®Google Scholar
• Klareskog L, Gaubitz M, Rodríguez-Valverde V, Malaise M, Dougados M, Wajdula J. 2011. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol. 29:238–247.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager J, Gough A, Kalden J, Mola E, Martín Mola E, Pavelka K, Sany J, Settas L, et al. 2004. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet. 363:675–681.
   PubMed Web of Science ®Google Scholar
• Moreland L, Schiff M, Baumgartner S, Tindall E, Fleischmann R, Bulpitt K, Weaver A, Keystone E, Furst D, Mease P, et al. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 130:478–486.
   PubMed Web of Science ®Google Scholar
• Roger S. 2010. Biosimilars: Current status and future directions. Expert Opin Biol Ther. 10:1011–1018.
   PubMed Web of Science ®Google Scholar
• Rondon F. 2010. Etanar therapy in real-life patients with rheumatoid arthritis [abstract]. Arthritis Rheumat. 62(Suppl 10):1811.
   Google Scholar
• Santos-Moreno P. 2015. Clinical outcomes in a cohort of Colombian patients with rheumatoid arthritis treated with Etanar, a new biologic type rhTNFR:Fc. Clin Exp Rheumatol. 33:858–862.
   PubMed Web of Science ®Google Scholar
• Santos-Moreno P. 2016. Direct comparative effectiveness among 3 anti-tumor necrosis factor biologics in a real-life cohort of patients With rheumatoid arthritis. J Clin Rheumatol. 22:57–62.
   PubMed Web of Science ®Google Scholar
• Shukla A, Thömmes J. 2010. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 28:253–261.
   PubMed Web of Science ®Google Scholar
• Singh J, Christensen R, Wells G, Suarez-Almazor M, Buchbinder R, Lopez-Olivo M, Ghogomu E, Tugwell P. 2009. Biologics for rheumatoid arthritis: An overview of Cochrane reviews. Cochrane Database Syst Rev. 4:CD007848.
   PubMed Web of Science ®Google Scholar
• van der Laan J, van Loveren H. 2005. Current status and burning issues in immunotoxicity testing of drugs. Toxicol Appl Pharmacol. 207:435–440.
   PubMedGoogle Scholar
• Venables W, Ripley B, editors. 2002. Modern applied statistics with issues of accuracy and scale. New York: Springer.
   Google Scholar
• Vincent F, Morand E, Murphy K, Mackay F, Mariette X, Marcelli C. 2013. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective. Ann Rheum Dis. 72:165–178.
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Kremer J, Bankhurst A, Bulpitt K, Fleischmann R, Fox R, Jackson C, Lange M, Burge D. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 340:253–259.
   PubMed Web of Science ®Google Scholar